$2.84
7.19%
Nasdaq, Sep 02, 10:18 pm CET
ISIN
US7995661045
Symbol
SANA

Sana Biotechnology Inc Stock price

$2.84
-1.39 32.86% 1M
+0.41 16.87% 6M
+1.21 74.23% YTD
-3.21 53.06% 1Y
-3.69 56.51% 3Y
-32.26 91.91% 5Y
-32.26 91.91% 10Y
-32.26 91.91% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.22 7.19%
ISIN
US7995661045
Symbol
SANA
Industry

Key metrics

Basic
Market capitalization
$734.7m
Enterprise Value
$662.0m
Net debt
positive
Cash
$72.7m
Shares outstanding
230.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.0
Financial Health
Equity Ratio
50.0%
Return on Equity
-106.5%
ROCE
-64.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-196.4m | $-198.6m
EBIT
$-212.6m | $-203.9m
Net Income
$-252.2m | $-205.4m
Free Cash Flow
$-185.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
12.9% | 22.2%
EBIT
14.6% | 25.2%
Net Income
-3.0% | 23.0%
Free Cash Flow
35.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.8
Short interest
39.1%
Employees
194
Rev per Employee
$0.0
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Sana Biotechnology Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
86%
Hold
14%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
27% 27%
-
- Research and Development Expense 167 167
32% 32%
-
-196 -196
13% 13%
-
- Depreciation and Amortization 16 16
31% 31%
-
EBIT (Operating Income) EBIT -213 -213
15% 15%
-
Net Profit -252 -252
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
Seeking Alpha
about 10 hours ago
Sana Biotechnology, Inc. (NASDAQ:SANA ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President Thank you for being here. My name is Sam Semenkow, I'm one of the Biotech analysts here at Citi.
Neutral
GlobeNewsWire
8 days ago
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 194
Founded 2018
Website sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today